chrisvoncsefalvay/vaers-outcomes huggingface dataset:
It was reported in a newspaper article that an 18 year old formerly healthy female who on an unspecified date was vaccinated with a second dose of GARDASIL (lot number, injection site and route not reported). Subsequently the patient experienced migraine-type headache fainting episode after the first two shots but did not consider it as possible side effect. On an unknown date, the patient was vaccinated with a third dose of GARDASIL (lot number, injection site and route not reported). The patient experienced CHARLEY-HORSE-type pain in her right leg led to spasms and tremors, an irregular heartbeat and nausea so severe that she lost 15 pounds in one month and had to go on intravenous fluids. The patient also developed a red rash on her upper body around the same time. The patient went to see the physician, and the physician told her that she had a "conversion disorder", in which stress caused physiological symptoms. The patient reported that her ailments had been getting worse for months, ever since she got her third GARDASIL shot. The patient felt that her adverse events were related to therapy with GARDASIL but most of her physician did not consider GARDASIL a possible cause. The patient though that fainting episode eventually disabled her. The patient reported that " I have not walked in six months". This is one of several reports from the same source. No further information is available.
Prevnar administered in L knee instead of IM. Swelling monitored until swelling subside Mom to monitor at home.
vaccine expired on 20May2022, vial was initially stored in the refrigerator on 7JUN2022, vaccine administrated on 8JUN2022; No adverse event; 27 Patient received booster doses of expired Moderna Covid-19 vaccine; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (27 Patient received booster doses of expired Moderna Covid-19 vaccine), PRODUCT STORAGE ERROR (vaccine expired on 20May2022, vial was initially stored in the refrigerator on 7JUN2022, vaccine administrated on 8JUN2022) and NO ADVERSE EVENT (No adverse event) in a 69-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033K21-2A) for COVID-19 prophylaxis.     No Medical History information was reported.   On 09-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 02-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 30-Nov-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Jun-2022, received fourth dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 08-Jun-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (27 Patient received booster doses of expired Moderna Covid-19 vaccine). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (vaccine expired on 20May2022, vial was initially stored in the refrigerator on 7JUN2022, vaccine administrated on 8JUN2022). an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (27 Patient received booster doses of expired Moderna Covid-19 vaccine), PRODUCT STORAGE ERROR (vaccine expired on 20May2022, vial was initially stored in the refrigerator on 7JUN2022, vaccine administrated on 8JUN2022) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (27 Patient received booster doses of expired Moderna Covid-19 vaccine) and PRODUCT STORAGE ERROR (vaccine expired on 20May2022, vial was initially stored in the refrigerator on 7JUN2022, vaccine administrated on 8JUN2022).    Concomitant medication information was not provided by the reporter.  The vial did not undergo any temperature excursions.  Treatment information was not provided by the reporter.   This case was linked to MOD-2022-642647.   Most recent FOLLOW-UP information incorporated above includes: On 01-Sep-2022: Follow-up received contains suspect product details added. On 02-Sep-2022: Follow-up received contains no new information
Severe rash at injection; itchy; measles like dots on fingers toes and lips and other isolated areas of body
Devel fever, high, tactile during noc of 11MAY92 p/recvd HIB/DTP/OPV & afternoon of 11MAY92; no other sx; examined 12MAY92 has questionable lt OM & fever of 104 R;
This spontaneous case was reported by an other health care professional and describes the occurrence of POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) in a 74-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 031L20A) for COVID-19 vaccination. No Medical History information was reported. On 12-Feb-2021 at 11:52 AM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .5 milliliter. On 12-Feb-2021 at 11:52 AM, the patient experienced POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). On an unknown date, the patient experienced PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021). At the time of the report, POOR QUALITY PRODUCT ADMINISTERED (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) and PRODUCT TEMPERATURE EXCURSION ISSUE (Doses administered after more than 1 temperature excursion during a period of 33 weeks on 2021) outcome was unknown. For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments. Age of patient was reported as 74.54 for dose administered on 12-Feb-2021. No concomitant medications were reported. Batch number 031L20A administered on 12-Feb-2021 underwent temperature excursion with temperature range of 35 degrees Fahrenheit at 11:00 AM. This vial was moved to fridge on 09-Feb-2021 and beyond use date for the vial was reported as 10-Mar-2021. Product moved to clinic on 12-Feb-2021. Vial was in cooler storage and was not in frozen storage during high-pace COVID-19 vaccination at around 2021. Vials were only punctured right before administration. Vaccines were not frozen at time of administration. It was reported that each time a vial was put into a cooler, sometimes there was a period of 1 hour or 1 hour and a half approximately, when temperature data logger registered a temperature of 34- or 35-degree Fahrenheit. Temperature recordings were taken using a Fisherbrand traceable temperature monitor at every hour. No treatment medications were reported.
RN reported second hand that an adult female patient, had received Fluzone through RN's company who give public flu shots. It was reported by the patient's husband that she had a seizure during the night just 4 days after receiving Fluzone. Their doctor could find nothing wrong.
Headache; itchy; Achy joints; confusion; Tiredness; nauseous; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 14Apr2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included mitral valve prolapse, set episodes and anxiety. The patient was allergic to shellfish and Intravenous Pyelogram (IVP) contrast dye. Concomitant medications included bupropion XL (MANUFACTURER UNKNOWN), taken for an unspecified indication from an unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 31Mar2021 at 12:00 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021, the patient experienced headache, itchy, achy joints, confusion, tiredness and felt nauseous. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events headache, itchy, achy joints, confusion, tiredness and felt nauseous were not resolved at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Initial soreness following the injection resolved within 24 hours, but 9 days after receiving injection, I noticed a red, slightly raised area around and mostly below the injection site, along with a small red dot which I assume was the actual site.  I have not yet recovered because I just noticed it earlier today.  For a couple of days prior, I had some mild itching which may  have been due to contact dermatitis.
body aches; Lethargic; Got really sick; Chills; Fever; Tired; Vomiting,couldn't keep anything down; Headaches,symptoms felt stronger when she took vaccine than when she actually had covid; This spontaneous case was reported by a consumer and describes the occurrence of LETHARGY (Lethargic), ILLNESS (Got really sick), CHILLS (Chills), PYREXIA (Fever) and FATIGUE (Tired) in a 44-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. Unknown) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included COVID-19.    On 29-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 29-Jan-2021, the patient experienced LETHARGY (Lethargic), ILLNESS (Got really sick), CHILLS (Chills), PYREXIA (Fever), FATIGUE (Tired), VOMITING (Vomiting,couldn't keep anything down) and HEADACHE (Headaches,symptoms felt stronger when she took vaccine than when she actually had covid). On an unknown date, the patient experienced MYALGIA (body aches). At the time of the report, LETHARGY (Lethargic), ILLNESS (Got really sick), CHILLS (Chills), PYREXIA (Fever), FATIGUE (Tired), VOMITING (Vomiting,couldn't keep anything down), HEADACHE (Headaches,symptoms felt stronger when she took vaccine than when she actually had covid) and MYALGIA (body aches) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medication was mentioned. No treatment medication was mentioned.
Received communication from Home Office that vaccine could be potentially short-dated and expired at the time of administration
Dose administered to patient after more than 30 days of storage in the fridge prior to first use; Dose administered to patient after more than 30 days of storage in the fridge prior to first use; This spontaneous case was reported by a pharmacist and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Dose administered to patient after more than 30 days of storage in the fridge prior to first use) and PRODUCT STORAGE ERROR (Dose administered to patient after more than 30 days of storage in the fridge prior to first use) in a 27-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 033H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 05-Feb-2022, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 05-Feb-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Dose administered to patient after more than 30 days of storage in the fridge prior to first use) and PRODUCT STORAGE ERROR (Dose administered to patient after more than 30 days of storage in the fridge prior to first use). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Dose administered to patient after more than 30 days of storage in the fridge prior to first use) and PRODUCT STORAGE ERROR (Dose administered to patient after more than 30 days of storage in the fridge prior to first use) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   The 4 vials were stored in the fridge since 22-Dec-2021 and did not undergo temperature excursions.  The patient received the booster dose of the vaccine.  No concomitant medication details was provided. No treatment medication details was provided.   This case was linked to MOD-2022-482129 (Patient Link).
This spontaneous report was received from a healthcare worker concerning unspecified patients of unknown age and gender. The reporter stated that on unspecified dates, since 11-MAY-2015, unspecified patients have been administered doses of improperly stored RECOMBIVAX HB (dose, frequency and route of administration not reported) lot # J006511, expiration date 28-JAN-2016 (also reported as 28-FEB-2016) exposed to temperatures outside of the recommended range. No adverse experience has been reported. This is one of several reports received from the same source. Additional information has been requested.
Pt with rash, fever and swollen glands 21 days after MMR, VARIVAX and DAPTACEL vaccine.  Mother convinced sx related to MMR vaccine.  One wk post vacc. got "chicken pox" rash; & fever; 15 days post vaccine dev. rash; post auricular lymphadenopathy & fever.
A couple minutes after the vaccine injection, patient complained of nausea and dizziness. She then proceeded to tell pharmacy staff that she has difficulty breathing and feels like she is going to black out. Pharmacist administered Epipen to patient and called 911.
The event involved vaccination with the influenza vaccine, Hep A # 2 and DTaP # 4 on 19 Oct 10 and later that evening he developed diarrhea, low grade fever and a rash on his cheeks. The diarrhea persisted for 3 wks when he was hospitalized on 08 Nov at hospital for dehydration. His stool was neg for O&P, Rotavirus Ag, Giardia, leukocytes, and C-diff. Diarrhea resolved, he was discharged and underwent a GI evaluation with endoscopy which noted one small area with eosinophils. He was evaluated by infectious disease with no further workup required. He underwent an allergy evaluation in which he was mildly positive for egg white IgE at 0.40, wheat and rye, and unclear significance of eosinophils on bx report. He is noted to have a mild eczematous rash on his face. Mom reports no problems with egg products. The pt also had a recurrence of diarrhea at the end of May for about 1-2 wks.
Woke up from sleep body aches fever and cold sweats feeling nauseous and fatigued
Hives and rash on skin; Hives and rash on skin; This is a spontaneous report from a contactable consumer. This consumer (patient) reported for female patient that,  A 19-years-old non pregnant female patient received bnt162b2 (BNT162B2, Formulation: Solution for injection, Batch/Lot Number: EW0169) (at the age of 19 years old), dose 1 via an unspecified route of administration, administered in arm left on 20Apr2021 as dose 1, single, dose 2 via an unspecified route of administration, administered in arm left on 11May2021 10:00 (Formulation: Solution for injection, Batch/Lot Number: EW0179) as dose 2, single for covid-19 immunisation. The patient medical history was not reported. Concomitant medication(s) included ascorbic acid (VITAMIN-C) taken within two weeks of vaccination for an unspecified indication, start and stop date were not reported. It was reported that on 12May2021 17:30 patient experienced urticaria and rash on skin. No treatment was received for events. No known allergies was reported. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. Prior to vaccination, patient was not diagnosed with COVID-19. Since the vaccination, patient had not been tested for COVID-19. Outcome for events was unknown.  Follow-up attempts are completed. No further information is expected.
Pulmonary embolism and bilateral DVTs, received vaccine on 3/11/21, was admitted to the hospital on 3/29/21
Episodes of extreme tinnitus several times a day and night, sometimes for hours at a time! I've NEVER experienced this before.
Initial consumer report received on 16 Feb 2011: This polymedicated patient with a current condition of "bad back", COPD and emphysema, received Influenza virus vaccine seasonal (manufacturer unknown, batch number unknown) on an unknown date. The patient had a big blue spot on arm which was painful. The patient went to the hospital. The symptoms went away and came again on an unknown date. The patient used warm pad and was taking pain pills. The outcome was not reported.
A report was received from a health care professional on 16 October 2001 regarding a 42 year old female patient who experienced an injection site reaction on 12 October 2001 after receiving fluvirin vaccine (batch E04861KA) on 11 October 2001. The patient received the flu vaccine the year before without a problem. Twenty four hours following the vaccination, the patient developed a 5-10 mm wheal and peripheral blisters. No treatment was undertaken and the wheal and blisters resolved on their own 3 days later. There was insufficient information to determine the reporter's causality assessment.
No reactions at the time of administration.  SOB came on gradually over 30 days.  Pt also had heart palpitations.
Mother reported severe arm pain for 1 week, studdering for 1 week, memory loss of memories the day before, skin rash on face and hands, loss of "eye focus" control.  Symptoms are gone now.  Patient has not been treated but will be seeing her doctor to get checked.
Patient had initially filled out online questionnaire for Pfizer vaccine and made appointment for 10/30. Patient came in evening around 7pm 10/29 and asked if she could get vaccine tonight, and requested we change to Moderna. Changed to Moderna, as requested. Prepared IMZ, spoke to patient, who appeared very nervous when I called her over for shot. Patient mentioned that she has a pseudoseizure disorder and fibromyalgia. Patient requested her husband come into the IMZ booth with her to calm her, which he did. Went into IMZ booth to give patient her Moderna shot (dose#1). Administered dose 1 and patient immediately seemed to be out of it. Her eyes were glazed, and she started complaining her arm hurt tremendously. I told her she was okay, and I was going to be right back. Went to get patient water and a cold compress. Returned, pt took a sip of water, and started trembling. Patient appeared to have seizure, as eyes closed, unable to speak, and trembled. Patient's husband sat with patient while I called 911 (one tech on break, one tech helping someone on other end of pharmacy). I immediately called 911, who dispatched paramedics. Code white was called, and management responded. Shot was given approx 7:12pm, paramedics arrived approx 7:30pm. Paramedics delivered at least one ( but I believe a second dose was also given) doses of Versed. Patient did not respond to Versed. Paramedics took her blood pressure, blood sugar, all stable. Patient did not stop trembling while paramedics were here. Paramedics loaded patient onto stretcher and took her to local hospital.
Narrative: 01/12, Moderna , dose #1 02/09, Moderna , dose #2 08/25 COVID swab, result: detected 09/07 COVID swab, result; detected 09/07 pt cc: asymptomatic exposure: unknown 09/30 COVID swab, result: NOT detected
Information has been received from a Licensed Vocational nurse concerning a 52 year old female with allergies to codeine and DEMEROL and history of migraine and urinary tract infection, at time of vaccination who on 14-APR-2009 was vaccinated with first dose of ZOSTAVAX (Merck) (route unspecified, lot number: 663176/1554X) in her left deltoid at 14:22. On 15-APR-2009 at 15:00, the patient experienced fever, body aches, muscle pain over all body, decreased appetite and headache. On 20-APR-2009, the patient's laboratory test results showed elevated liver enzymes (see laboratory test section). The patient's test results on 20-APR-2009 also indicated that the patient had an increased glucose level (109 mg/dL; normal range 70-105 mg/dL). The patient's test results on 21-APR-2009 indicated that the patient had a low iron level (55 ug/dL; normal range 70-180 ug/dL). The outcome of the patient's increased glucose and low iron were unknown. The patient was also referred for an abdominal ultrasound for the elevated liver enzymes and abdominal pain (onset of abdominal pain was not reported). Results indicated that the liver had a "heterogeneous echotexture, although definable mass noted involving the liver" (also reported as "no definable mass noted involving liver"). The tail of pancreas was obscured by bowel and could not be evaluated. The head and body of the pancreas were visualized and were unremarkable. If patient continued to be symptomatic, further evaluation with CT would be recommended. The liver was otherwise remarkable. No abnormalities noted involving the spleen, left kidney, right kidney, abdominal aorta, or inferior vena cava. The patient was referred to gastroenterology for evaluation. The patient's outcome was unknown. Additional information has been requested.
Rash left arm and is painful. Also warm to touch. Pt. given cephalexin 500mg one cap TID x7 days.
A light reaction, bumps, but got worse since he was scratching. They turned into welts by Sunday. On Saturday they got pretty bad so he took an oatmeal bath and BENADRYL, which calmed it down. There was intense itching, visible hives which were growing and multiplying. Feet were hurting specially thumbs because they were swollen and joints aching; it hurt to walk. No fever. Monday checked in with nurse who mentioned that if problems continued to go to the ER. Pt has not missed school. Today hives were gone, no BENADRYL required, soles of feet swollen and tender and has a headache.
Systemic: Allergic: Difficulty breathing-Medium, Systemic: Allergic: Difficulty swallowing, throat tightness-Medium, Systemic: Allergic: Itch generalized-Medium, Systemic: Allergic: Rash generalized-Medium, Systemic: Allergic: Swelling of face/eyes/mouth/tongue-Medium.
Nausea; Headache; This is a spontaneous report from contactable consumer. A female patient of unspecified age received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE; Solution for injection; Lot number: Unknown), via an unspecified route of administration on an unspecified date as dose number unknown, single for COVID-19 immunization. The patient medical history and concomitant medications were not reported. On an unspecified date, the patient experienced nausea and headache. The outcome of events was unknown.  Information on the lot/batch number has been requested  Follow-up (14MAY2021): Follow-up attempts completed. No further information expected.
About 1/2hr. after receiving the vaccine, patient's cheeks were red.  About 1 1/2 hours after receiving the vaccine, he started itching.  Rash notice on his back, described as looking like a measles rash.  He also had 2 hives on his neck. Legs looked mottled, but no rash or itching.  Rash lasted approximately 4-5 hours. By 9pm, the rash was gone.  He slept well and has no rash this morning.